A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment

Published: 12/16/2024

Author: FRC Analysts

Thumbnail of the report A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment

*This report and research coverage is paid for and commissioned by NurExone Biologic Inc. - See the bottom of this report for other important disclosures rating, and risk definitions. All figures in C$ unless otherwise specified.

Sector: Healthcare | Industry: Biotechnology

Ticker Symbols:NRX.V - TSX 🔹

Rating and Key Data

Metrics	Value
Current Price	CAD $0.77
Fair Value	CAD $2
Risk	5
52 Week Range	CAD $0.26-1.19
Shares O/S (M)	71
Market Cap. (M)	CAD $55
Current Yield (%)	N/A
P/E (forward)	N/A
P/B	N/A

Already a subscriber?

Want to know the fair value of the stock?

Subscribe for free to get exclusive insights and data.

Report Highlights

NRX, an Israeli biotech company founded in 2020, is developing a novel drug delivery platform designed to provide minimally invasive, highly targeted solutions to address unmet medical needs.
The company leverages exosomes, tiny, naturally occurring cellular sacs, to deliver medication directly to inflamed or damaged tissues. This targeted approach offers potential advantages over traditional gene and cell therapies. While the exosome therapeutics industry is emerging, there are currently no FDA-approved products.

NRX is focused on treating central nervous system injuries, spinal cord injury (SCI), optic nerve injury, brain trauma, and neurological conditions through regenerative medicine. Its lead pro

Rating and Key Data

Metrics	Value
Current Price	CAD $0.77
Fair Value	CAD $2
Risk	5
52 Week Range	CAD $0.26-1.19
Shares O/S (M)	71
Market Cap. (M)	CAD $55
Current Yield (%)	N/A
P/E (forward)	N/A
P/B	N/A